- Defence Therapeutics (DTC) has been granted a U.S. patent covering conjugated compounds permitting delivery of antibodies to the nucleus using its Accum technology
- Accum is the first solution for the precision delivery method for improved intracellular antibody-drug conjugate (ADC) routing, reducing toxicity in healthy cells
- Accum enables ADCs to control intracellular delivery of chemotherapeutic drugs
- Defence Therapeutics is a biotechnology company engineering the next generation of vaccines and antibody drug conjugates
- Defence Therapeutics (DTC) opened trading at C$2.12
Defence Therapeutics (DTC) has been granted a U.S. patent covering conjugated compounds permitting delivery of antibodies to the nucleus using its Accum technology.
Accum is the first solution for the precision delivery method for improved intracellular antibody-drug conjugate (ADC) routing. Overcoming problematic cell recycling and rejection patterns, Accum enables ADCs to control intracellular delivery of chemotherapeutic drugs, resulting in superior preclinical anti-tumour activity and reducing toxicity in healthy cells.
Sébastien Plouffe, CEO of Defence Therapeutics, commented on the news.
“This U.S. patent is an important milestone in protecting the commercial potential of Accum directly related to our ADC program. Defence is expecting key ADC in vivo results in a few weeks from independent ADCs studies ongoing in Europe. Defence’s commitment to protect the innovation is crucial as its ADC development and ADC interest applied in oncology is advancing rapidly.”
According to Precedence Research Predicts, the global oncology market size is expected to worth around US$536.01 billion by 2029. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
The global antibody drug conjugates market size is expected to reach over US$22.87 billion by 2030 according to a recent 2022 report by Grand View Research Inc.
Defence Therapeutics is a biotechnology company engineering the next generation of vaccines and antibody drug conjugates.
Defence Therapeutics (DTC) opened trading at C$2.12.
